Clinical trial
A Phase 1b/2a, Multi-Center, Open-Label，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JAB-3068 in Combination With JS001 in Patients With Advanced Solid Tumors
NCT04721223 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2a, Multi-Center, Open-Label，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JAB-3068 in Combination With JS001 in Patients With Advanced Solid Tumors
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 26, 2021
- Completion date
- December 29, 2023
- Enrollment
- 12 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, non small cell lung cancer